Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% YoY. Check out why I ...

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the ...

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the ...

CEO Andrew Dudum said the funds will allow the company to grow internationally and invest in artificial intelligence.